Literature DB >> 8048954

Transcription of the human apolipoprotein A-II is down-regulated by the first intron of its gene.

J P Bossu1, F L Chartier, N Vu-Dac, J C Fruchart, B Laine.   

Abstract

Several reports indicate that apoA-II, the second most abundant HDL protein, plays a crucial role in modulating the anti-atherogenic behavior of HDL. Regulatory elements located 5' to the human apoA-II promoter have been previously described. In this paper we report that the first intron of the human apoA-II gene down-regulates its own promoter and the ubiquitous thymidine kinase promoter both in HepG2 and Caco-2 cells. The intron contains three sequences which bind nuclear proteins, thus demonstrating the presence of regulatory elements downstream of the transcription start site of the apoA-II gene.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8048954     DOI: 10.1006/bbrc.1994.2004

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Setting the course for apoAII: a port in sight?

Authors:  Henry J Pownall; Baiba K Gillard; Antonio M Gotto
Journal:  Clin Lipidol       Date:  2013-10

2.  Retinoids increase human apolipoprotein A-11 expression through activation of the retinoid X receptor but not the retinoic acid receptor.

Authors:  N Vu-Dac; K Schoonjans; V Kosykh; J Dallongeville; R A Heyman; B Staels; J Auwerx
Journal:  Mol Cell Biol       Date:  1996-07       Impact factor: 4.272

3.  Two regulatory elements of similar structure and placed in tandem account for the repressive activity of the first intron of the human apolipoprotein A-II gene.

Authors:  J P Bossu; F L Chartier; J C Fruchart; J Auwerx; B Staels; B Laine
Journal:  Biochem J       Date:  1996-09-01       Impact factor: 3.857

4.  Fibrates increase human apolipoprotein A-II expression through activation of the peroxisome proliferator-activated receptor.

Authors:  N Vu-Dac; K Schoonjans; V Kosykh; J Dallongeville; J C Fruchart; B Staels; J Auwerx
Journal:  J Clin Invest       Date:  1995-08       Impact factor: 14.808

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.